The next 5 years in medicine: the therapies on the way

Every few weeks, a headline promises a medical revolution. Most fade quietly within a year. But some of what is currently sitting in late-stage clinical trials has a realistic chance of reaching everyday practice within this decade. Here is a grounded look at six areas worth watching between now and 2031, based on published trial data rather than press releases.

Personalised mRNA cancer vaccines

In August 2026, Moderna and Merck announced that their personalised mRNA cancer vaccine, given together with the immunotherapy pembrolizumab, met its primary endpoint in a phase 3 trial in patients with melanoma who had already had surgery. The vaccine is built from each patient’s own tumour DNA, teaching the immune system to recognise mutations unique to that cancer. It is the first personalised cancer vaccine to succeed in a randomised phase 3 trial, and it points toward a future where some cancer treatments are manufactured individually rather than off a shelf.

Gene editing beyond sickle cell disease

Casgevy, a CRISPR-based gene editing treatment, has been approved since 2023 for sickle cell disease and beta thalassemia, with strong results: in trials, 16 of 17 sickle cell patients and 25 of 27 thalassemia patients no longer needed the treatments that previously defined their lives. What is new is where the technology is heading next. Base editing therapies aimed at cardiovascular risk, targeting genes such as PCSK9, ANGPTL3 and Lp(a), have shown LDL cholesterol reductions of up to around 59% in early trials, raising the idea of a one-time treatment instead of a daily pill. These are still early or mid-stage trials, and long-term safety data will take years to mature.

A new generation of weight-loss medicines

Retatrutide, developed by Eli Lilly, acts on three hormone receptors at once (GLP-1, glucagon and GIP), rather than the single receptor targeted by earlier medicines. In the phase 3 TRIUMPH-1 trial, participants on the highest weekly dose (12 mg) lost an average of 28.3% of their body weight over 80 weeks, a result researchers describe as approaching the outcomes seen with bariatric surgery. Nausea, diarrhoea and constipation remain common side effects. Eli Lilly has said it expects to file for approval in 2027.

Alzheimer’s disease: a wider net of targets

The 2026 Alzheimer’s drug pipeline includes 192 clinical trials testing 158 different drugs, a meaningful increase from a decade ago. What has changed is the strategy: amyloid-targeted drugs have gone from about a third of the pipeline to roughly a fifth, while treatments aimed at tau protein and at inflammation have each grown to a similar share. Despite this activity, there is still no approved disease-modifying treatment for people with early (preclinical) or with moderate to severe disease, and several phase 3 results are expected over the next one to two years.

Longevity drugs: more enthusiasm than evidence, for now

Rapamycin, a drug that inhibits a cellular growth pathway called mTOR, is the most discussed candidate in the longevity space, promoted by some as mimicking the effects of caloric restriction. In the PEARL trial, low-dose intermittent use was well tolerated over one year, with only modest changes in biological ageing markers, and researchers are honest that these markers do not yet reliably predict real-world benefit. Rapamycin also carries real risks, including mouth ulcers, delayed wound healing and metabolic side effects. For now, there is no solid evidence to support healthy people taking it to slow ageing.

Psychedelic-assisted therapy for treatment-resistant depression

COMP360, a synthesised form of psilocybin developed by Compass Pathways, showed statistically significant results in two phase 3 trials for treatment-resistant depression, meaning depression that has not responded to at least two previous antidepressants. Around 40% of participants responded after two guided sessions three weeks apart. The company expects to file for FDA approval in late 2026, with a possible launch in the United States in the first half of 2027, always administered under clinical supervision rather than as a take-home medicine.

A successful trial is not the same as an approved treatment, and an approved treatment is not the same as something available to every patient who might benefit. Timelines in medicine tend to slip. It is worth staying informed without postponing decisions about your health while waiting for a headline to become a prescription.

This article is for information only and does not replace a medical consultation.